Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.5618
-0.0473-7.77%
Post-market: 0.57600.0142+2.53%19:48 EST
Volume:2.67M
Turnover:1.54M
Market Cap:121.63M
PE:-0.75
High:0.6091
Open:0.6090
Low:0.5618
Close:0.6091
52wk High:2.35
52wk Low:0.3600
Shares:216.51M
Float Shares:205.84M
Volume Ratio:0.66
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7500
EPS(LYR):-1.3101
ROE:-96.44%
ROA:-49.48%
PB:1.47
PE(LYR):-0.43

Loading ...

e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up

TIPRANKS
·
Yesterday

Tenaya Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
Yesterday

Column Group III GP, LP Disposes of Tenaya Therapeutics Common Shares

Reuters
·
Feb 27

Column Group III GP, LP reports disposal of Tenaya Therapeutics common shares

Reuters
·
Feb 25

Major Tenaya Therapeutics Stake Dumped by Key Shareholder in Eye‑Catching Move

TIPRANKS
·
Feb 13

Column Group III GP, LP Reports Disposal of Tenaya Therapeutics Inc. Common Shares

Reuters
·
Feb 13

Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan

TIPRANKS
·
Jan 31

Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise

Simply Wall St.
·
Jan 23

Tenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating

TIPRANKS
·
Jan 10

Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating

TIPRANKS
·
Jan 10

BRIEF-Tenaya Therapeutics Announces 2026 Strategic Priorities

Reuters
·
Jan 09

Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027

Reuters
·
Jan 09

Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-201 in 2026

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-401 in H2 2026

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics Inc - Raised $60 Mln in 4Q25 to Support Runway Through Mid-2027

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics - Expects to Report One-Year Cohort 1 Data & Early Cohort 2 Data From Ridge-1 Study of Tn-401 for Pkp2-Associated Arvc in H1 2026

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

GlobeNewswire
·
Jan 09

Tenaya Therapeutics Director David Goeddel Resigns Effective January 2026

Reuters
·
Jan 03

Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 19, 2025

Tenaya Therapeutics (TNYA) Is Down 39.7% After FDA Lifts TN-201 Hold and Trial Updates - What's Changed

Simply Wall St.
·
Dec 13, 2025